Bristol Myers Squibb Non-GAAP EPS of $1.96 beats by $0.07, revenue of $11.6B beats by $260M

Apr. 29, 2022 7:01 AM ETBristol-Myers Squibb Company (BMY)By: Gaurav Batavia, SA News Editor8 Comments
  • Bristol Myers Squibb press release (NYSE:BMY): Q1 Non-GAAP EPS of $1.96 beats by $0.07.
  • Revenue of $11.6B (+4.8% Y/Y) beats by $260M.
  • Total revenue in-line with 2021  (from low single digit increase) vs. $47.1B consensus
  •  EPS of $7.65-$7.95 vs. $7.74 consensus
  • Revenue breakdown: Revlimid of $2.79B, Eliquis of $3.21B and Opdivo of $1.92B.

Recommended For You

Comments (8)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.